Novavax's Head Of Vaccine Research To Participate In WHO Meeting To Develop Global Action Plan For Pandemic Influenza PR Newswire - May 01, 2006 09:27
MALVERN, Pa., May 1, 2006 /PRNewswire-FirstCall via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that its Vice President of Vaccine Research, Dr. Rick Bright, will participate in the World Health Organization (WHO) meeting for the development of a global action plan for increasing pandemic vaccine supply to develop a plan to alleviate the global shortage of pandemic influenza vaccines. Dr. Bright will join leading scientists, industry, and public health experts from around the world at the meeting, to be held this week at WHO headquarters in Geneva, Switzerland.
"I am extremely pleased to have been invited to participate in this important meeting," Dr. Bright said. "A dialogue between researchers, industry, and public health experts is the best way to develop an approach to protect people around the world from the potentially debilitating effects of influenza." Dr. Bright has more than 15 years of experience as a researcher and is an expert on influenza vaccine and antiviral research, one of a handful of such experts in the world. Prior to joining Novavax in February, 2006, he served at the Centers for Disease Control (CDC) and Prevention in Atlanta, GA.
Representatives from national immunization programs, regulatory authorities, and vaccine manufacturers from both industrialized as well as developing countries also will participate in the meeting. More information on the meeting can be obtained from the WHO website at http://www.who.int/csr/disease/influenza/vaccinesconsult2006/en/index.html
THE THRILL OF VICTORY ;-) & THE AGONY OF DEFEAT ;-(
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.